Thomas Crampton helps VC funds and their portfolio companies to position themselves for follow-on capital.
A former foreign correspondent for The New York Times and International Herald Tribune, Thomas went on to hold global leadership roles at the marketing and communications agencies Ogilvy & Mather and Edelman before moving into startups, including help co-found a healthtech start-up from a Zoom call through Series A as well as lead all of Corporate Affairs at GreenLight Biosciences for the biotech’s Nasdaq listing as a Unicorn.
Existe el riesgo de que los científicos retrasen la adopción de sus propias innovaciones simplemente por su forma de comunicar. Estos enfoques pueden cambiar eso.
There is a risk that scientists will slow the adoption of their own innovations simply by their way of communication. These approaches can significantly increase support.
